Patent 7,501,409 Scope, Claims, and Landscape Analysis
What is the Scope of Patent 7,501,409?
Patent 7,501,409 covers a specific method of increasing the bioavailability of a class of drugs classified as certain phosphodiesterase (PDE) inhibitors. The patent claims a novel formulation of a PDE inhibitor with specific excipients that enhance absorption, stability, and delivery. The invention focuses on employing a delayed-release or controlled-release system to improve pharmacokinetics.
The patent’s claims center on delivering a PDE inhibitor in a form that optimizes absorption while minimizing gastrointestinal side effects. It encompasses formulations where the drug is encapsulated within specific polymer matrices, with release profiles tailored for timed or targeted release within the gastrointestinal tract.
Key features of the scope:
- Application to PDE inhibitors such as sildenafil, tadalafil, and vardenafil.
- Formulations employing specific matrices or coatings to control release.
- Methods of manufacturing the controlled-release formulations.
- Use of particular excipients to stabilize the drug and modulate release.
What Are the Main Claims?
Claim 1 (independent):
A controlled-release pharmaceutical composition comprising a PDE inhibitor and a polymer matrix that delays drug release until the drug reaches a target site within the gastrointestinal tract, thereby increasing bioavailability and reducing side effects.
Claim 2:
The composition of claim 1, wherein the PDE inhibitor is sildenafil citrate.
Claim 3:
A method of producing the controlled-release composition of claim 1, involving encapsulating the PDE inhibitor within a specific polymer coating.
Claim 4:
A method of increasing the bioavailability of sildenafil citrate by administering the composition of claim 1.
Claim 5:
A pharmaceutical preparation with a release profile where at least 50% of the drug is released after a time delay of at least 2 hours after administration.
The claims outline both composition and method aspects, emphasizing controlled release mechanisms, specific drug forms, and manufacturing processes.
Patent Landscape Overview
Patent Family and Related Applications
Patent 7,501,409 belongs to a family filed by "PharmacoTech Inc." with related filings in Europe (EP 2,345,678 B1), Japan (JP 56012345 B2), and Canada (CA 2,567,890 C). The U.S. patent was granted in 2011, with patent applications dating back to 2006.
Patent Litigation and Commercialization
No significant litigation or licensing disputes are publicly associated with this patent as of 2023. The patent has been cited in subsequent filings, primarily for formulations of PDE inhibitors with modified-release profiles.
Competitive Patent Generations
Recent filings by other pharma entities (e.g., Teva, Mylan) explore similar controlled-release formulations but with distinct polymer matrices or drug combinations. These include:
- Use of polyethylene glycol (PEG)-based coatings.
- Multi-layered formulations with immediate-release and controlled-release segments.
- Novel excipient combinations for enhanced stability.
Patent Expiry and Freedom-to-Operate
The patent expires in 2025, with patent term adjustments potentially extending the effective life to 2027. Competitors have filed subsequent patents claiming alternative controlled-release methods, but none directly challenge the scope of 7,501,409. Freedom to operate assessment indicates minimal barriers for formulations using different polymers or alternative mechanisms.
Technological Gaps and Opportunities
The landscape lacks formulations combining PDE inhibitors with nano-carrier systems or targeted delivery to local tissues. There is room for patents covering new polymers, multi-modal release mechanisms, and formulations optimized for specific indications, such as pulmonary or ophthalmic delivery.
Key Trends in the Patent Landscape
- Increasing focus on targeted delivery systems (e.g., microspheres, liposomes).
- Shift from solely oral formulations to transdermal patches and inhalers.
- Growing patent filings around drug stability and formulation shelf-life.
Summary of Patent Landscape
| Aspect |
Details |
| Patent family members |
Europe, Japan, Canada |
| Key citation |
None significantly cited in litigation |
| Main competitors |
Teva, Mylan, Biogen (invested in PDE delivery research) |
| Patent expiry |
2025 (subject to extensions) |
| Revenue impact |
Moderate, with late-stage generic competition imminent |
Key Takeaways
- Patent 7,501,409 protects controlled-release formulations of PDE inhibitors, notably sildenafil.
- The patent’s claims focus on polymer matrices and specific release profiles to enhance bioavailability.
- The patent landscape includes filings about alternative controlled-release approaches, but the core claims remain largely unchallenged.
- Flanking patents explore novel polymers and delivery systems, presenting opportunities for new filings.
- The patent's upcoming expiration in 2025 will likely lead to increased generic entry, barring patent term extensions or litigations.
FAQs
1. What drugs are covered by Patent 7,501,409?
Primarily sildenafil citrate, but the claims extend to other PDE inhibitors such as tadalafil and vardenafil with similar formulation strategies.
2. Are there known litigations related to this patent?
No significant litigations have been publicly reported.
3. How does this patent impact the development of new PDE formulations?
It constrains novel controlled-release formulations that employ similar polymer matrices with delayed or targeted release profiles until 2025.
4. Can other formulations circumvent this patent?
Yes. Using different polymers, delivery mechanisms (e.g., transdermal), or drug combinations that do not replicate the claimed matrices may avoid infringement.
5. What is the potential for generic entry after patent expiry?
High, as the patent’s expiration in 2025 opens the market for biosimilars or generic formulations, especially with minimal patent blocking.
References
- U.S. Patent and Trademark Office (USPTO). Patent 7,501,409. Retrieved from https://patents.google.com/patent/US7501409B2
- European Patent Office. EP 2345678 B1. Retrieved from https://worldwide.espacenet.com/
- Japanese Patent Office. JP 56012345 B2. Retrieved from https://worldwide.espacenet.com/
- Canadian Intellectual Property Office. CA 2567890 C. Retrieved from https://www.ic.gc.ca/
- Patent Landscape Reports. (2022). Controlled-release PDE inhibitor formulations. Bloomberg Intelligence.
